Skip to content
Research Article Open access CC BY 4.0

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): What Can Africa Learn from Ongoing Research in Epidemiology, Clinical Manifestations, Chemotherapy and Prevention?

Silas Lendzele Sevidzem, Aubin Armel Koumba, Christophe Roland Zinga- Koumba, Nonvignon Marius Kedote, Gaël Darren Maganga, Essé Elvire Agossou, Safiatou Niaré- Doumbo, Bitsha-Kitime Dieudoné Kabkia, Luc Salako Djogbenou, Genevieve Lydie Acapovi- Yao, Idrissa Sarr, Julien Zahouli Bi Zahouli, Chimène Nze- Nkoghé, Rodrigue Mintsa- Nguema, Athanase Badolo, Emmanuel Kamba Mebourou, Jacques François Mavoungou, Fatou Bintou Sarr

Asian Journal of Medicine and Health · pp. 17–27 · Published 25 Jun 2020

10.9734/ajmah/2020/v18i630213

Abstract

The world is experiencing an outbreak due to the new and mysterious SARS-CoV-2. Information regarding its source and transmission dynamics in different environments as well as medications for its prevention and cure is weak. This review seeks to document on the epidemiology, clinical signs, control, prevention, and present some perspectives for SARS-CoV-2 research in Africa. There are geographical differences in morbidity and mortality rates of this disease all over the world. The scientific community strongly reject claims regarding the fact that the virus has been genetically manipulated, but supports the theory that it has a natural origin from animal host as any other emerging viral disease. Although animals are thought to be the original source of global spill over, person-to-person transmission is well comprehended. Transmission could be enhanced by symptomatic and asymptomatic individuals with high contaminations reported in dense urban environments. Scientific evidences from the Center for Disease Control (CDC) and other publications reported that contaminated surfaces and air could possibly be the underlying mechanism through which SARS-CoV-2 spreads. Cohort studies reveal that children as well as adults could be vulnerable to the disease, but others attribute it to health care workers, some risky habits (drinking and smoking) and comorbid individuals due to their immune suppressed status. There is no drug of choice for SARS-CoV-2, but clinical studies including several antiviral drugs are underway. Similarly, vaccine studies and clinical trial studies are ongoing. Because there is no medication, preventive measures such as Personal Protective Equipments (PPEs), ventilators, sanitation, social distancing, and quarantine are the gears globally used to curb the spread of this virus. The African continent does not have high morbidity and mortality compared to other continents that are highly affected. The following lessons could be learned by Africans from ongoing research: that the SARS-CoV-2 originated from an animal host, individuals could be infected irrespective of their age, sex, race, and origin, there is a broad spectrum of clinical signs and confirmatory diagnosis is required, there is no approved drug of choice, vaccine trials are ongoing and community-based prevention is required, the recommendations put in place by the Government and the WHO to curb the spread of this virus should be strictly followed. From the above lessons, a research project to study the ecological epidemiology of SARS-CoV-2 in tropical African settings by including the following aspects: socio-cultural, economic, and political characteristics as well as the evaluation of measures taken by the different countries to combat the disease is required.

SARS-CoV-2 epidemiology clinical signs chemotherapy prevention Africa

References (61)

  1. 1 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [DOI]
  2. 2 A pneumonia outbreak associated with a new coronavirus of probable bat origin [DOI]
  3. 3 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [DOI]
  4. 4 Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 [DOI]
  5. 5 The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak [DOI]
  6. 6 The proximal origin of SARS-CoV-2 [DOI]
  7. 7 RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [DOI]
  8. 8 Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study [DOI]
  9. 9 Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) [DOI]
  10. 10 Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China [DOI]
  11. 11 The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro [DOI]
  12. 12 Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient [DOI]
  13. 13 Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins [DOI]
  14. 14 Chloroquine is a potent inhibitor of SARS coronavirus infection and spread [DOI]
  15. 15 The outbreak of COVID-19: An overview [DOI]
  16. 16 Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings [DOI]
  17. 17 Virology, Epidemiology, Pathogenesis, and Control of COVID-19 [DOI]
  18. 18 Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China [DOI]
  19. 19 Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease [DOI]
  20. 20 Discovering drugs to treat coronavirus disease 2019 (COVID-19) [DOI]
  21. 21 Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study [DOI]
  22. 22 Effects of chloroquine on viral infections: an old drug against today's diseases [DOI]
  23. 23 New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? [DOI]
  24. 24 Coronavirus Pathogenesis [DOI]
  25. 25 Laboratory diagnosis of emerging human coronavirus infections – the state of the art [DOI]
  26. 26 Rule of Law and Constitutional Democracy [DOI]
  27. 27 Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection [DOI]
  28. 28 Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir [DOI]
  29. 29 Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis [DOI]
  30. 30 COVID-19 Disease due to SARS-CoV-2 (Novel Coronavirus) [DOI]
  31. 31 Host Factors in Coronavirus Replication [DOI]
  32. 32 Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection [DOI]
  33. 33 Evolutionary history, potential intermediate animal host, and cross‐species analyses of SARS‐CoV‐2 [DOI]
  34. 34 Inactivation of feline calicivirus, a Norwalk virus surrogate [DOI]
  35. 35 Transmission potential of the novel coronavirus (COVID-19) onboard the diamond Princess Cruises Ship, 2020 [DOI]
  36. 36 Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19 [DOI]
  37. 37 Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge [DOI]
  38. 38 COVID-19: Zoonotic aspects [DOI]
  39. 39 Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study [DOI]
  40. 40 Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics) [DOI]
  41. 41 Novel coronavirus disease (COVID-19) in children [DOI]
  42. 42 Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors [DOI]
  43. 43 Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity [DOI]
  44. 44 An Efficient COVID-19 Prediction Model Validated with the Cases of China, Italy and Spain: Total or Partial Lockdowns? [DOI]
  45. 45 HIV/AIDS infection prevalence in an agriculture-dominated rural community of west region of Cameroon [DOI]
  46. 46 Typhoid, Malaria and their Concurrent Infections in Fondonera, West Region of Cameroon [DOI]
  47. 47 Correlation between universal BCG vaccination policy and reduced mortality for COVID-19 [DOI]
  48. 48 Epidemiological data from the COVID-19 outbreak, real-time case information [DOI]
  49. 49 Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis [DOI]
  50. 50 Epidemic Growth and Reproduction Number for the Novel Coronavirus Disease (COVID-19) Outbreak on the Diamond Princess Cruise Ship from January 20 to February 19, 2020: A preliminary Data-Driven Analysis [DOI]
  51. 51 Home visits: a strategy to improve newborn survival - Authors' reply [DOI]
  52. 52 Prevention and control of non-communicable diseases in the COVID-19 response [DOI]
  53. 53 Dynamic interventions to control COVID-19 pandemic: a multivariate prediction modelling study comparing 16 worldwide countries [DOI]
  54. 54 Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy [DOI]
  55. 55 COVID-19 Surface Persistence: A Recent Data Summary and Its Importance for Medical and Dental Settings [DOI]
  56. 56 Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2 [DOI]
  57. 57 Fangcang shelter hospitals during the COVID-19 epidemic, Wuhan, China [DOI]
  58. 58 Genetic diversity and ecology of coronaviruses hosted by cave-dwelling bats in Gabon [DOI]
  59. 59 Cluster of COVID-19 in northern France: A retrospective closed cohort study [DOI]
  60. 60 Combination prevention for COVID-19 [DOI]
  61. 61 Clinical, Laboratory and Imaging Features of COVID-19: A Systematic Review and Meta-analysis [DOI]

Cited by 1

Lessons Learned After Two Years of Living with COVID-19: A Special Focus on Findings from Multidisciplinary Pan African Studies

S. Lendzele, Agossou A. Essé, K. Armel · 2022

Related research

Article metrics

Real usage data collected on this platform.

40

Page views

0

PDF downloads

18

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.